Epithelial-Mesenchymal Transition in Human Prostate Cancer Demonstrates Enhanced Immune Evasion Marked by IDO1 Expression
- PMID: 29921693
- DOI: 10.1158/0008-5472.CAN-17-3752
Epithelial-Mesenchymal Transition in Human Prostate Cancer Demonstrates Enhanced Immune Evasion Marked by IDO1 Expression
Abstract
Cancer invasion and metastasis are driven by epithelial-mesenchymal transition (EMT), yet the exact mechanisms that account for EMT in clinical prostate cancer are not fully understood. Expression of N-cadherin is considered a hallmark of EMT in clinical prostate cancer. In this study, we determined the molecular mechanisms associated with N-cadherin expression in patients with prostate cancer. We performed laser capture microdissection of matched N-cadherin-positive and -negative prostate cancer areas from patient samples (n = 8), followed by RNA sequencing. N-cadherin expression was significantly associated with an immune-regulatory signature including profound upregulation of indoleamine 2,3-dioxygenase (IDO1; log2-fold change = 5.1; P = 2.98E-04). Fluorescent immunostainings of patient samples confirmed expression of IDO1 protein and also its metabolite kynurenine in primarily N-cadherin-positive areas. N-cadherin-positive areas also exhibited a local decrease of intraepithelial cytotoxic (CD8+) T cells and an increase of immunosuppressive regulatory T cells (CD4+/FOXP3+). In conclusion, EMT in clinical prostate cancer is accompanied by upregulated expression of IDO1 and an increased number of regulatory T cells. These data indicate that EMT, which is an important step in tumor progression, can be protected from effective immune control in patients with prostate cancer.Significance: These findings demonstrate EMT is linked to an immunosuppressive environment in clinical prostate cancer, suggesting that patients with prostate cancer can potentially benefit from combinatorial drug therapy. Cancer Res; 78(16); 4671-9. ©2018 AACR.
©2018 American Association for Cancer Research.
Similar articles
-
N-cadherin promotes epithelial-mesenchymal transition and cancer stem cell-like traits via ErbB signaling in prostate cancer cells.Int J Oncol. 2016 Feb;48(2):595-606. doi: 10.3892/ijo.2015.3270. Epub 2015 Nov 26. Int J Oncol. 2016. PMID: 26647992
-
Differential expression of epithelial and mesenchymal proteins in a panel of prostate cancer cell lines.J Urol. 2012 Aug;188(2):632-8. doi: 10.1016/j.juro.2012.03.114. Epub 2012 Jun 15. J Urol. 2012. PMID: 22704442
-
Upregulation of long non-coding RNA PlncRNA-1 promotes proliferation and induces epithelial-mesenchymal transition in prostate cancer.Oncotarget. 2017 Apr 18;8(16):26090-26099. doi: 10.18632/oncotarget.15318. Oncotarget. 2017. PMID: 28212533 Free PMC article.
-
Epithelial-Mesenchymal Transition (EMT) and Prostate Cancer.Adv Exp Med Biol. 2018;1095:101-110. doi: 10.1007/978-3-319-95693-0_6. Adv Exp Med Biol. 2018. PMID: 30229551 Review.
-
The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges.Cells. 2019 Sep 20;8(10):1118. doi: 10.3390/cells8101118. Cells. 2019. PMID: 31547193 Free PMC article. Review.
Cited by
-
Discovery of novel IDO1 inhibitors via structure-based virtual screening and biological assays.J Comput Aided Mol Des. 2021 May;35(5):679-694. doi: 10.1007/s10822-021-00386-6. Epub 2021 Apr 27. J Comput Aided Mol Des. 2021. PMID: 33905074
-
LncRNA KCNQ1OT1 sponges miR-15a to promote immune evasion and malignant progression of prostate cancer via up-regulating PD-L1.Cancer Cell Int. 2020 Aug 15;20:394. doi: 10.1186/s12935-020-01481-8. eCollection 2020. Cancer Cell Int. 2020. PMID: 32821247 Free PMC article.
-
Intergrated analysis of ELMO1, serves as a link between tumour mutation burden and epithelial-mesenchymal transition in hepatocellular carcinoma.EBioMedicine. 2019 Aug;46:105-118. doi: 10.1016/j.ebiom.2019.07.002. Epub 2019 Jul 16. EBioMedicine. 2019. PMID: 31324602 Free PMC article.
-
Role of Interleukin-1 family in bone metastasis of prostate cancer.Front Oncol. 2022 Sep 27;12:951167. doi: 10.3389/fonc.2022.951167. eCollection 2022. Front Oncol. 2022. PMID: 36237303 Free PMC article. Review.
-
Modelling aggressive prostate cancers of young men in immune-competent mice, driven by isogenic Trp53 alterations and Pten loss.Cell Death Dis. 2022 Sep 8;13(9):777. doi: 10.1038/s41419-022-05211-y. Cell Death Dis. 2022. PMID: 36075907 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials